Cargando…
The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum
BACKGROUND: Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested. METHODS: A randomized, open-label trial was conducted comparing...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662869/ https://www.ncbi.nlm.nih.gov/pubmed/19291301 http://dx.doi.org/10.1186/1475-2875-8-48 |
_version_ | 1782165881533497344 |
---|---|
author | Sirima, Sodiomon B Tiono, Alfred B Gansané, Adama Diarra, Amidou Ouédraogo, Amidou Konaté, Amadou T Kiechel, Jean René Morgan, Caroline C Olliaro, Piero L Taylor, Walter RJ |
author_facet | Sirima, Sodiomon B Tiono, Alfred B Gansané, Adama Diarra, Amidou Ouédraogo, Amidou Konaté, Amadou T Kiechel, Jean René Morgan, Caroline C Olliaro, Piero L Taylor, Walter RJ |
author_sort | Sirima, Sodiomon B |
collection | PubMed |
description | BACKGROUND: Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested. METHODS: A randomized, open-label trial was conducted comparing the efficacy (non-inferiority design) and safety of fixed (F) dose AS (25 mg)/AQ (67.5 mg) to loose (L) AS (50 mg) + AQ (153 mg) in 750, P. falciparum-infected children from Burkina Faso aged 6 months to 5 years. Dosing was by age. Primary efficacy endpoint was Day (D) 28, PCR-corrected, parasitological cure rate. Recipients of rescue treatment were counted as failures and new infections as cured. Documented, common toxicity criteria (CTC) graded adverse events (AEs) defined safety. RESULTS: Recruited and evaluable children numbered 750 (375/arm) and 682 (90.9%), respectively. There were 8 (AS/AQ) and 6 (AS+AQ) early treatment failures and one D7 failure (AS+AQ). Sixteen (AS/AQ) and 12 (AS+AQ) patients had recurrent parasitaemia (PCR new infections 10 and 6, respectively). Fourteen patients per arm required rescue treatment for vomiting/spitting out study drugs. Efficacy rates were 92.1% in both arms: AS/AQ = 315/342 (95% CI: 88.7–94.7) vs. AS+AQ = 313/340 (95% CI: 88.6–94.7). Non-inferiority was demonstrated at two-sided α = 0.05: Δ (AS+AQ – AS/AQ) = 0.0% (95% CI: -4.1% to 4.0%). D28, Kaplan Meier PCR-corrected cure rates (all randomized children) were similar: 93.7% (AS/AQ) vs. 93.2% (AS+AQ) Δ = -0.5 (95% CI -4.2 to 3.0%). By D2, both arms had rapid parasite (F & L, 97.8% aparasitaemic) and fever (97.2% [F], 96.0% [L] afebrile) clearances. Both treatments were well tolerated. Drug-induced vomiting numbered 8/375 (2.1%) and 6/375 (1.6%) in the fixed and loose arms, respectively (p = 0.59). One patient developed asymptomatic, CTC grade 4 hepatitis (AST 1052, ALT 936). Technical difficulties precluded the assessment and risk of neutropaenia for all patients. CONCLUSION: Fixed dose AS/AQ was efficacious and well tolerated. These data support the use of this new fixed dose combination for treating P. falciparum malaria with continued safety monitoring. TRIAL REGISTRATION: Current Controlled Trials ISRCTN07576538 |
format | Text |
id | pubmed-2662869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26628692009-03-31 The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum Sirima, Sodiomon B Tiono, Alfred B Gansané, Adama Diarra, Amidou Ouédraogo, Amidou Konaté, Amadou T Kiechel, Jean René Morgan, Caroline C Olliaro, Piero L Taylor, Walter RJ Malar J Research BACKGROUND: Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ is new, but its safety and efficacy are hitherto untested. METHODS: A randomized, open-label trial was conducted comparing the efficacy (non-inferiority design) and safety of fixed (F) dose AS (25 mg)/AQ (67.5 mg) to loose (L) AS (50 mg) + AQ (153 mg) in 750, P. falciparum-infected children from Burkina Faso aged 6 months to 5 years. Dosing was by age. Primary efficacy endpoint was Day (D) 28, PCR-corrected, parasitological cure rate. Recipients of rescue treatment were counted as failures and new infections as cured. Documented, common toxicity criteria (CTC) graded adverse events (AEs) defined safety. RESULTS: Recruited and evaluable children numbered 750 (375/arm) and 682 (90.9%), respectively. There were 8 (AS/AQ) and 6 (AS+AQ) early treatment failures and one D7 failure (AS+AQ). Sixteen (AS/AQ) and 12 (AS+AQ) patients had recurrent parasitaemia (PCR new infections 10 and 6, respectively). Fourteen patients per arm required rescue treatment for vomiting/spitting out study drugs. Efficacy rates were 92.1% in both arms: AS/AQ = 315/342 (95% CI: 88.7–94.7) vs. AS+AQ = 313/340 (95% CI: 88.6–94.7). Non-inferiority was demonstrated at two-sided α = 0.05: Δ (AS+AQ – AS/AQ) = 0.0% (95% CI: -4.1% to 4.0%). D28, Kaplan Meier PCR-corrected cure rates (all randomized children) were similar: 93.7% (AS/AQ) vs. 93.2% (AS+AQ) Δ = -0.5 (95% CI -4.2 to 3.0%). By D2, both arms had rapid parasite (F & L, 97.8% aparasitaemic) and fever (97.2% [F], 96.0% [L] afebrile) clearances. Both treatments were well tolerated. Drug-induced vomiting numbered 8/375 (2.1%) and 6/375 (1.6%) in the fixed and loose arms, respectively (p = 0.59). One patient developed asymptomatic, CTC grade 4 hepatitis (AST 1052, ALT 936). Technical difficulties precluded the assessment and risk of neutropaenia for all patients. CONCLUSION: Fixed dose AS/AQ was efficacious and well tolerated. These data support the use of this new fixed dose combination for treating P. falciparum malaria with continued safety monitoring. TRIAL REGISTRATION: Current Controlled Trials ISRCTN07576538 BioMed Central 2009-03-16 /pmc/articles/PMC2662869/ /pubmed/19291301 http://dx.doi.org/10.1186/1475-2875-8-48 Text en Copyright © 2009 Sirima et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sirima, Sodiomon B Tiono, Alfred B Gansané, Adama Diarra, Amidou Ouédraogo, Amidou Konaté, Amadou T Kiechel, Jean René Morgan, Caroline C Olliaro, Piero L Taylor, Walter RJ The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum |
title | The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum |
title_full | The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum |
title_fullStr | The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum |
title_full_unstemmed | The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum |
title_short | The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum |
title_sort | efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young african children with acute uncomplicated plasmodium falciparum |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662869/ https://www.ncbi.nlm.nih.gov/pubmed/19291301 http://dx.doi.org/10.1186/1475-2875-8-48 |
work_keys_str_mv | AT sirimasodiomonb theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT tionoalfredb theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT gansaneadama theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT diarraamidou theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT ouedraogoamidou theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT konateamadout theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT kiecheljeanrene theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT morgancarolinec theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT olliaropierol theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT taylorwalterrj theefficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT sirimasodiomonb efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT tionoalfredb efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT gansaneadama efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT diarraamidou efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT ouedraogoamidou efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT konateamadout efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT kiecheljeanrene efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT morgancarolinec efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT olliaropierol efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum AT taylorwalterrj efficacyandsafetyofanewfixeddosecombinationofamodiaquineandartesunateinyoungafricanchildrenwithacuteuncomplicatedplasmodiumfalciparum |